AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8744464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g every 24 hours for two doses
Number of subjects: 20
Study 8744464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 20
Study 8744464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 20
Study 1928271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.3%
Number of subjects: 288
Study 1928271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 1928271 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 0.3%
Number of subjects: 288
Study 6350878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine and prednisone
Number of subjects: 209
Study 6350878 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (azathioprine and prednisone)
Number of subjects: 209
Study 6350878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine and prednisone (with kidneys perfused by machine for longer than 24 hours)
Number of subjects: 209
Study 6350878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine and prednisone (with surgical anastomosis time longer than 45 minutes)
Number of subjects: 209
Study 30615299 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles
Number of subjects: 62
Study 30615299 — intervention group
Group type: COMPARATOR
Intervention: Neutral insoles
Number of subjects: 62
Study 29800529 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral strength training with eccentric contractions
Number of subjects: 0
Study 29800529 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 27167669 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding for 1 week in healthy volunteers
Number of subjects: 0
Study 27167669 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding for 2 weeks in patients with Crohn's disease
Number of subjects: 0
Study 25528932 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 88
Study 25528932 — intervention group
Group type: COMPARATOR
Intervention: Continuous Moderate Exercise (CME)
Number of subjects: 88
Study 25528932 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 88
Study 22100536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 981
Study 22100536 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 981
Study 22100536 — intervention group
Group type: EXPERIMENTAL
Intervention: MAC adjudicated causes of death
Number of subjects: 981
Study 22100536 — intervention group
Group type: EXPERIMENTAL
Intervention: MAC vs SI agreement
Number of subjects: 981
Study 20203376 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional TENS (one-time trial management program)
Number of subjects: 27
Study 20203376 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional TENS (one-week trial management program)
Number of subjects: 27
Study 20203376 — intervention group
Group type: COMPARATOR
Intervention: Control group (fifteen healthy children)
Number of subjects: 27
Study 17657970 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol therapy using 'Dovolenskaya' mineral water
Number of subjects: 0
Study 15831534 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity shivering (5 degrees C)
Number of subjects: 0
Study 15831534 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity shivering (10 degrees C)
Number of subjects: 0
Study 12019591 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity programs at worksites
Number of subjects: 8
Study 9445330 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol
Number of subjects: 2253
Study 9445330 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐36
Number of subjects: 2253
Study 9445330 — intervention group
Group type: COMPARATOR
Intervention: Both EuroQol and SF‐36
Number of subjects: 2253
Study 7625344 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g.kg body wt-1.d-1 of a mixed protein diet (70% derived from vegetable sources)
Number of subjects: 7
Study 7625344 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g.kg body wt-1.d-1 of a mixed protein diet (70% derived from vegetable sources)
Number of subjects: 7
Study 7625344 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g.kg body wt-1.d-1 of a mixed protein diet (70% derived from vegetable sources)
Number of subjects: 7
Study 7625344 — intervention group
Group type: COMPARATOR
Intervention: 1.2 g.kg body wt-1.d-1 of a high-quality mixed protein diet (80% from animal sources)
Number of subjects: 7
Study 30703179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Cards (photographic images co-created by an artist and chronic pain patients)
Number of subjects: 119
Study 30703179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Cards
Number of subjects: 119
Study 29151701 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter selective SMA urokinase infusion therapy
Number of subjects: 40
Study 29151701 — intervention group
Group type: COMPARATOR
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 40
Study 25052366 — intervention group
Group type: EXPERIMENTAL
Intervention: PPC-5650
Number of subjects: 25
Study 25052366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 23266205 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique
Number of subjects: 110
Study 23266205 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 110
Study 21699794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) in a maximum of 3 infusions of 1000 or 500 mg iron
Number of subjects: 485
Study 21699794 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (IS) with Ganzoni-calculated dosages in up to 11 infusions of 200 mg iron
Number of subjects: 485
Study 19194376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytidine
Number of subjects: 35
Study 19194376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 17531572 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin plus provisional glycoprotein IIb/IIIa blockade
Number of subjects: 1371
Study 17531572 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus planned glycoprotein IIb/IIIa blockade
Number of subjects: 1371
Study 17531572 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic patients
Number of subjects: 1371
Study 17531572 — intervention group
Group type: COMPARATOR
Intervention: Nonanemic patients
Number of subjects: 1371
Study 15073684 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 376
Study 15073684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 11309551 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of furosemide plus 250 mg of probenecid
Number of subjects: 100
Study 11309551 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of furosemide plus 1000 mg of probenecid
Number of subjects: 100
Study 11309551 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 20 mg of furosemide
Number of subjects: 100
Study 9495430 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress hormone cocktail (epinephrine, cortisol, glucagon, angiotensin II, and vasopressin) administered intravenously for 24 hours
Number of subjects: 17
Study 9495430 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 17
Study 8039523 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise plus dietary restriction (45-60 min/day at 50%-60% VO2max, 3-4 days/week, energy deficit of -1.05 to -1.14 MJ/day)
Number of subjects: 32
Study 8039523 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise plus dietary restriction
Number of subjects: 32
Study 8039523 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 2666238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifuroxazide 400 mg twice daily for 5 days
Number of subjects: 88
Study 2666238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 2666238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifuroxazide
Number of subjects: 88
Study 1103550 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 20
Study 1103550 — intervention group
Group type: COMPARATOR
Intervention: Diphenylhydantoin (DPH)
Number of subjects: 20
Study 1103550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean serum levels
Number of subjects: 20
Study 1103550 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effectiveness
Number of subjects: 20
Study 29665619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate Extract (PE) - D2 (656 mg phenolics)
Number of subjects: 49
Study 29665619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate Extract (PE) - D2
Number of subjects: 49
Study 28376767 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU vitamin D3 weekly
Number of subjects: 68
Study 28376767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 26132895 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% sucrose solution (SUC)
Number of subjects: 14
Study 26132895 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric sweetened placebo (PLA)
Number of subjects: 14
Study 21599832 — intervention group
Group type: EXPERIMENTAL
Intervention: High insertion torque implants (MIT > 70 Ncm, mean = 110.6 Ncm, range: 70.8‐176 Ncm)
Number of subjects: 48
Study 21599832 — intervention group
Group type: COMPARATOR
Intervention: Low insertion torque implants (control group, MIT between 30 and 50 Ncm, mean = 37.1 Ncm)
Number of subjects: 48
Study 21436223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual cannabis extract (maximum of 10.8 mg tetrahydrocannabinol and 10 mg cannabidiol)
Number of subjects: 9
Study 21436223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 18472662 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment episode
Number of subjects: 176
Study 18472662 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional treatment after initial outpatient episode
Number of subjects: 176
Study 18472662 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment only
Number of subjects: 176
Study 18472662 — intervention group
Group type: EXPERIMENTAL
Intervention: Various combinations of outpatient, intensive outpatient, and residential treatment
Number of subjects: 176
Study 17130515 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 17130515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian ablation
Number of subjects: 0
Study 17130515 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced amenorrhea
Number of subjects: 0
Study 14581111 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsicum plaster
Number of subjects: 320
Study 14581111 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 320
Study 10897061 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN plus NAC (3MU IFN-alpha thrice weekly plus NAC 1800 mg daily)
Number of subjects: 147
Study 10897061 — intervention group
Group type: COMPARATOR
Intervention: IFN alone
Number of subjects: 147
Study 10897061 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN plus NAC
Number of subjects: 147
Study 8819554 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose 24% (S24, n = 8)
Number of subjects: 28
Study 8819554 — intervention group
Group type: COMPARATOR
Intervention: Sucrose 12% (S12, n = 8)
Number of subjects: 28
Study 8819554 — intervention group
Group type: COMPARATOR
Intervention: Spring water (W, n = 12)
Number of subjects: 28
Study 1420739 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole o.m.
Number of subjects: 241
Study 1420739 — intervention group
Group type: COMPARATOR
Intervention: 40 mg famotidine nocte
Number of subjects: 241
Study 3917660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 33
Study 3917660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 33
Study 3917660 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume loading with nitroglycerin
Number of subjects: 33
Study 3917660 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume loading with nitroprusside
Number of subjects: 33
Study 31728054 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Intensification (DI)
Number of subjects: 0
Study 31728054 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour intravenous methotrexate (IV MTX) infusion (1 g/m2)
Number of subjects: 0
Study 31728054 — intervention group
Group type: COMPARATOR
Intervention: 4-hour intravenous methotrexate (IV MTX) infusion (2 g/m2)
Number of subjects: 0
Study 31728054 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) <0.01%
Number of subjects: 0
Study 31728054 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) ≥0.01%
Number of subjects: 0
Study 29529157 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle intervention with partial meal replacement
Number of subjects: 257
Study 29529157 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 257
Study 26282334 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching one's own back (visual feedback)
Number of subjects: 19
Study 26282334 — intervention group
Group type: COMPARATOR
Intervention: Watching a neutral object (book)
Number of subjects: 19
Study 26282334 — intervention group
Group type: COMPARATOR
Intervention: Watching a video of another person of the same sex
Number of subjects: 19
Study 26282334 — intervention group
Group type: COMPARATOR
Intervention: Watching a picture of the own back
Number of subjects: 19
Study 26282334 — intervention group
Group type: COMPARATOR
Intervention: Keeping one's eyes closed
Number of subjects: 19
Study 24877778 — intervention group
Group type: EXPERIMENTAL
Intervention: Medienhelden program (ten-week curriculum)
Number of subjects: 570
Study 24877778 — intervention group
Group type: EXPERIMENTAL
Intervention: Medienhelden program (single project day)
Number of subjects: 570
Study 24877778 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 570
Study 22290342 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive self-management (CSM) intervention
Number of subjects: 175
Study 22290342 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 175
Study 20238247 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release esomeprazole 60 mg od
Number of subjects: 55
Study 20238247 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release esomeprazole 80 mg od
Number of subjects: 55
Study 20238247 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release esomeprazole 40 mg od
Number of subjects: 55
Study 20238247 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation esomeprazole 20 mg bid
Number of subjects: 55
Study 20238247 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation esomeprazole 40 mg bid
Number of subjects: 55
Study 17662431 — intervention group
Group type: EXPERIMENTAL
Intervention: Verisyse pIOL
Number of subjects: 11
Study 17662431 — intervention group
Group type: EXPERIMENTAL
Intervention: Artiflex pIOL
Number of subjects: 11
Study 17662431 — intervention group
Group type: COMPARATOR
Intervention: Both pIOLs
Number of subjects: 11
Study 15464320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 70
Study 15464320 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 70
Study 11246179 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured preoperative instructions
Number of subjects: 0
Study 9589225 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-energy formula diet (1,100 ± 250 kcal/day)
Number of subjects: 20
Study 9589225 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (6.3 ± 0.4 kg)
Number of subjects: 20
Study 7992938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparine (0.3 mL, 3,075 anti Xa IU per day, one daily subcutaneous injection)
Number of subjects: 480
Study 7992938 — intervention group
Group type: COMPARATOR
Intervention: Calciparine (0.2 mL t.i.d., 15,000 IU per day, one subcutaneous injection)
Number of subjects: 480
Study 7992938 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 480
Study 2514323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (Benzodiazepine antagonist)
Number of subjects: 30
Study 2514323 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 30
Study 2514323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30852528 — intervention group
Group type: EXPERIMENTAL
Intervention: HeART of Stroke (HoS) intervention (ten 2-hour sessions over 14 weeks) plus usual care
Number of subjects: 56
Study 30852528 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 56
Study 29170073 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 212
Study 29170073 — intervention group
Group type: COMPARATOR
Intervention: No intravenous fentanyl (control)
Number of subjects: 212
Study 27000445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 1110
Study 27000445 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1110
Study 25255113 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted T-shaped reduction
Number of subjects: 255
Study 25255113 — intervention group
Group type: COMPARATOR
Intervention: Vertical scar reduction
Number of subjects: 255
Study 25255113 — intervention group
Group type: COMPARATOR
Intervention: Vertical scar reduction (for reductions less than 500 g)
Number of subjects: 255
Study 22221076 — intervention group
Group type: EXPERIMENTAL
Intervention: telcagepant (280-mg tablet/300-mg capsule)
Number of subjects: 165
Study 22221076 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 165
Study 20669013 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg three times daily for 3 days)
Number of subjects: 18
Study 20669013 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study 20669013 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg three times daily for 3 days) in CYP2C19 HEMs and PMs
Number of subjects: 18
Study 20669013 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg three times daily for 3 days) in CYP2C19 EMs
Number of subjects: 18
Study 20669013 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotypes (EMs, HEMs, PMs)
Number of subjects: 18
Study 17573359 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoCapture devices with steroid‐eluting epicardial leads
Number of subjects: 56
Study 16288378 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP205 vaccine formulation (10(6.08) TCID(50))
Number of subjects: 0
Study 16288378 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP205 vaccine formulation (10(6.33) TCID(50))
Number of subjects: 0
Study 16288378 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP205 vaccine (both formulations)
Number of subjects: 0
Study 16288378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11843746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (40%) by facemask
Number of subjects: 69
Study 11843746 — intervention group
Group type: EXPERIMENTAL
Intervention: Air by facemask
Number of subjects: 69
Study 11843746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen at 2 l x min(‐1) by nasal cannulae
Number of subjects: 69
Study 11843746 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 69
Study 11843746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannulae
Number of subjects: 69
Study 10078402 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms.kg‐1
Number of subjects: 73
Study 10078402 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 73
Study 10078402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 7675371 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceed (TC7) Absorbable Adhesion Barrier
Number of subjects: 32
Study 7675371 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 32
Study 2116747 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding (16 days, 1,000 kcal above usual intake)
Number of subjects: 10
Study 2116747 — intervention group
Group type: COMPARATOR
Intervention: Sham feeding (16 days, 100 kcal above usual intake)
Number of subjects: 10
Study 6992131 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 6992131 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study 6992131 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal subjects)
Number of subjects: 0
Study 31182134 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP intervention (training for pharmacy staff and environmental prompts)
Number of subjects: 60
Study 31182134 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 31182134 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP intervention
Number of subjects: 60
Study 28438906 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model for diagnosis of ACI
Number of subjects: 260
Study 25491659 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician (MD) introduction
Number of subjects: 137
Study 25491659 — intervention group
Group type: COMPARATOR
Intervention: Non-physician (non-MD) introduction
Number of subjects: 137
Study 24662288 — intervention group
Group type: EXPERIMENTAL
Intervention: FX CorDiax 60
Number of subjects: 30
Study 24662288 — intervention group
Group type: COMPARATOR
Intervention: FX 60
Number of subjects: 30
Study 22365555 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (80 hours)
Number of subjects: 0
Study 22365555 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 0
Study 22365555 — intervention group
Group type: COMPARATOR
Intervention: Computer games control condition
Number of subjects: 0